EPCAM and hepatocellular carcinoma: Unlike doxorubicin, 5-FU and cisplatin challenged HCC cells showed a different EpCAM expression pattern, and this discrepancy implied that doxorubicin could target directly to EpCAM but not 5-FU and cisplatin.